Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | MicrobiomeTrials
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-31Est. Completion: 2026-08-17
Enrollment target: 497 participants
Locations
SEC Clinical Research, LLC, Dothan, Alabama, United States
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
Tucson Clinical Research Institute, Tucson, Arizona, United States
Downtown LA Research Center Inc - ClinEdge, Los Angeles, California, United States
California Medical Research Associates, Inc., Northridge, California, United States
Northern California Research Corp, Sacramento, California, United States
Clinical Research of West Florida Inc, Clearwater, Florida, United States
Fleming Island Center For Clinical Research, Fleming Island, Florida, United States
Florida Institute For Clinical Research LLC, Orlando, Florida, United States
Ormond Beach Clinical Research, Ormond Beach, Florida, United States
Progressive Medical Research, Port Orange, Florida, United States
Clinical Research of West Florida Inc - Tampa, Tampa, Florida, United States
Centricity Research Columbus Georgia Multispecialty - PPDS, Columbus, Georgia, United States
ASHA Clinical Research - Hammond, Hammond, Indiana, United States
Velocity Clinical Research - Valparaiso, Valparaiso, Indiana, United States
Other microbiome trials you might be interested in